A lung cancer drug that beat Keytruda in China was just turned down by the FDA, because U.S. trial patients didn’t clearly live longer
Ivonescimab slowed tumor growth, but the agency said that wasn’t enough without proof of longer survival. Here’s what the drug does, why it drew so much attention and what patients can use now.
The Food and Drug Administration has refused to approve ivonescimab, an experimental lung cancer drug, Summit Therapeutics said Sunday. Summit, a Miami-based drugmaker, had asked to sell it with chemotherapy for people whose lung cancer carries a change in a gene called EGFR and kept growing after targeted pills such as osimertinib, sold as Tagrisso.
The FDA sent a “complete response letter,” its formal way of saying an application can’t be approved as filed. According to Summit, the agency said the trial showed the drug slowed tumor growth, but did not prove that patients lived longer, and that slower growth alone was not enough to approve it for these patients.
What it means for patients
Ivonescimab stays unavailable in the U.S. outside research studies. People in this situation still have the treatment the FDA approved in September 2024: amivantamab, sold as Rybrevant, plus two chemotherapy drugs. In that drug’s main trial, cancer was held in check for a median of 6.3 months, versus 4.2 months with chemotherapy alone, the FDA said. Summit’s website lists its clinical trials and has a page on expanded access, a route some patients use to get unapproved drugs outside a trial. Patients should ask their cancer doctor which options fit them.
What the drug does
Ivonescimab is a “bispecific” antibody, a lab-made immune protein that grabs two targets at once. One is PD-1, a brake on immune cells; drugs like Keytruda release that brake so the immune system can attack cancer. The other is VEGF, a signal tumors use to grow new blood vessels; drugs like Avastin block it. The idea is to do both jobs with one molecule. No drug of this type is approved in the U.S., Summit said.
The drug was invented by Akeso, a Chinese drugmaker, which licensed U.S., European and Japanese rights to Summit, according to Summit. China approved it in May 2024. It became famous after a trial in China in which ivonescimab alone held lung cancer in check for a median of 11.1 months, versus 5.8 months for Keytruda, The Lancet reported02722-3/abstract). That trial tested a different group of patients than the one the FDA reviewed.
Why the FDA said no
The trial the FDA reviewed, called HARMONi, compared chemotherapy plus ivonescimab with chemotherapy plus a dummy drug. Patients on ivonescimab lived a median of 16.8 months, versus 14.0 months, Summit reported in July. But that gap fell short of the trial’s bar for statistical significance, the test of whether a result is likely real rather than chance. Later follow-up looked better, Summit said, but those extra analyses were done after the fact and could not replace the trial’s main test.
Why the decision follows the FDA’s rules
Living longer is the clearest proof a cancer drug works. The FDA’s guidance on cancer trial goals calls overall survival “the most reliable cancer endpoint” and says a drug’s effect on tumor growth can be larger than its effect on survival. Slower growth alone may or may not mean patients are better off, depending on the disease, the size of the effect and the drug’s risks, the guidance says.
HARMONi set survival as one of its two main goals before it began, and it missed that goal, according to Summit. The stronger survival numbers came from extra analyses chosen after the results were in, which can turn up patterns by chance, so regulators do not treat them as proof. Weighing a new drug’s side effects against slower growth with no proven survival gain, the FDA concluded the benefits did not clearly outweigh the risks, Summit said. Summit noted that no approved treatment in this setting has yet shown a survival gain.
Side effects were similar in both groups, according to Summit: 7.3% of patients stopped ivonescimab because of side effects, versus 5.0% who stopped the dummy drug.
Summit is testing the drug in other lung, colon, bladder and kidney cancers. Robert W. Duggan, Summit’s chairman and co-CEO, said the company is “disappointed for patients and their families.” The statement did not say whether Summit would reapply for this use.
Source: Summit Therapeutics, statement on the ivonescimab application, Nov. 15, 2026; Summit Therapeutics, HARMONi survival update, July 22, 2026 (SEC filing); The Lancet, HARMONi-2 trial abstract02722-3/abstract); FDA, amivantamab approval, Sept. 19, 2024; FDA guidance: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics (2018).
- Summit Therapeutics: Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application (Nov. 15, 2026)
- Summit Therapeutics: HARMONi updated overall survival release, July 22, 2026 (SEC EDGAR exhibit)
- The Lancet: Ivonescimab versus pembrolizumab for PD-L1-positive NSCLC (HARMONi-2)
- FDA: FDA approves amivantamab-vmjw with carboplatin and pemetrexed for NSCLC with EGFR exon 19 deletions or L858R mutations
- Summit Therapeutics: Akeso partnership page
- FDA: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics, guidance for industry (Dec. 2018; PDF https://www.fda.gov/media/71195/download)